DIODATI, LUCREZIA
 Distribuzione geografica
Continente #
NA - Nord America 322
EU - Europa 201
AS - Asia 40
AF - Africa 24
SA - Sud America 1
Totale 588
Nazione #
US - Stati Uniti d'America 321
IT - Italia 117
SE - Svezia 32
SG - Singapore 17
CI - Costa d'Avorio 14
DE - Germania 13
BG - Bulgaria 12
CN - Cina 10
FR - Francia 9
GB - Regno Unito 9
SN - Senegal 8
PL - Polonia 6
VN - Vietnam 6
IN - India 4
AT - Austria 2
HK - Hong Kong 2
NG - Nigeria 2
BR - Brasile 1
CA - Canada 1
IR - Iran 1
NL - Olanda 1
Totale 588
Città #
Chandler 43
Fairfield 42
Seattle 34
Milan 23
Ashburn 22
Houston 19
Pisa 18
Wilmington 18
Florence 17
Woodbridge 15
Abidjan 14
New York 12
Sofia 12
Frankfurt am Main 11
Princeton 10
Boardman 9
Cambridge 9
Dakar 8
Lawrence 8
Marseille 8
Ann Arbor 6
Livorno 6
Medford 6
Ogden 6
Rome 6
Dong Ket 5
Singapore 5
Warsaw 5
Beijing 3
Cascina 3
London 3
Naples 3
Bitritto 2
Busto Arsizio 2
Desio 2
Fairburn 2
Fisciano 2
Guangzhou 2
Hong Kong 2
Lagos 2
San Diego 2
Vauxhall 2
Vienna 2
Altamura 1
Amsterdam 1
Bremen 1
Carapicuiba 1
Carrara 1
Dallas 1
Dearborn 1
Hefei 1
Kilburn 1
Kish 1
Kunming 1
Los Angeles 1
Nanjing 1
Pittsburgh 1
Prato 1
Pune 1
Redwood City 1
San Francisco 1
San Giuliano Terme 1
Seacroft 1
Serra 1
Shanghai 1
Shenzhen 1
Toronto 1
Vicopisano 1
Washington 1
Totale 457
Nome #
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 122
ANKRd44 gene silencing: A putative role in trastuzumab resistance in HER2-like breast cancer 110
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 101
Androgen receptor expression inversely correlates with histological grade and N stage in ER+/PgRlow male breast cancer 76
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 70
Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview 48
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 45
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 36
Totale 608
Categoria #
all - tutte 2.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.826


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202092 0 0 0 8 10 12 12 14 12 11 11 2
2020/202169 8 9 0 6 0 1 3 2 12 12 7 9
2021/202288 2 0 0 2 19 14 6 8 4 3 11 19
2022/2023189 21 24 12 10 11 18 2 15 53 2 21 0
2023/2024135 10 16 18 17 16 20 9 11 2 3 6 7
2024/202513 3 10 0 0 0 0 0 0 0 0 0 0
Totale 608